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Editorials
Improving glycaemic control in children and adolescents presents unique problems
TYPE 1 DIABETES affects one in 500 children and adoles-
cents, and vascular complications remain a major cause of
mortality and morbidity in adult life. Blood glucose targets
have fallen since confirmation of the unequivocal relation-
ship between glycaemic control and microvascular compli-
cations.1,2 In this issue of the Journal (page 235), Craig et al
present a population-based, cross-sectional study of 1190
children and adolescents with type 1 diabetes in New South
Wales and the Australian Capital Territory.3 Their median
HbA1c level of 8.2% probably reflects
some selection bias, because 571 (33%)
of the population did not participate.
However, this level of glycaemic control
still represents a considerable improve-
ment over the past 10 years4 and is
comparable to levels found in interna-
tional studies of children with type 1
diabetes.5 This trend accompanies the increasing use of
intensive management in children and adolescents, but also
the worrying rise in the incidence of severe hypoglycaemia.
There are compelling reasons to recommend intensive
therapy in adolescents with type 1 diabetes — either multi-
ple daily injections or continuous subcutaneous insulin
infusion. The effectiveness of intensive therapy in improving
and maintaining good glycaemic control is well established
in adolescents under research trial conditions.6 More recent
data also indicate that the benefits of intensive therapy and
improved glycaemic control persist even when HbA1c levels
later rise.7 After completion of the Diabetes Control and
Complications Trial (DCCT), adolescents from the former
intensive therapy and conventional therapy groups returned
to routine care and were advised to use intensive therapy.
Despite no difference in their glycaemic control for four
years after the end of the DCCT, the benefits of previous
better control in the intensive therapy group persisted. Their
prevalence of progression to proliferative or severe non-
proliferative retinopathy was reduced by 78% during the
four years. Suboptimal control during adolescence appears
to have a lasting harmful effect, even when better glycaemic
control is achieved later.
Those caring for children and adolescents with type 1
diabetes may worry about the demands on the family and
child of achieving good glycaemic control with intensive
therapy. However, good glycaemic control is associated with
better quality-of-life scores (QOL) in adolescents and less
perceived burden by their parents.8 The intensity of the
insulin regimen does not adversely affect QOL. Clearly, the
demands of achieving good control are less than the conse-
quences of poor control.8
The limiting factor of achieving ideal glycaemic control
remains hypoglycaemia, excluding other problems of
adherence or family functioning. Adolescents in the
DCCT had higher rates of hypoglycaemia than their adult
counterparts, despite having higher HbA1c levels.
6 Gluca-
gon secretion, which stimulates hepatic glycogenolysis, is
blunted early in the course of type 1 diabetes, increasing
the patient’s vulnerability to hypoglycaemia. Further, the
blood glucose threshold level for catecholamine release in
response to hypoglycaemia is lowered in patients with
better glycaemic control and this counter-regulatory
response is most blunted during sleep.9 Recently available
continuous blood glucose monitoring devices have shown
that nocturnal hypoglycaemia is fre-
quent in children. However, both new
insulin analogues and continuous sub-
cutaneous insulin therapy hold promise
of improving control without the
attendant increased risk of hypo-
glycaemia. In Western Australia, chil-
dren with type 1 diabetes had more
hypoglycaemia in association with falling HbA1c levels until
1995;4 since then their control has improved further, but
without increased hypoglycaemia.
Can the DCCT recommendations that adolescents
receive intensive therapy be reproduced in routine care? The
Hvidore Study Group has followed more than 2500 children
and adolescents over three years in Europe, Canada and
Japan.5 Despite more use of intensive therapy, glycaemic
control did not necessarily improve with wide differences
between paediatric centres. Intensive therapy demands
intensive follow-up, education and support, as well as
resources that many Australian paediatric diabetes units do
not have if most patients are to be supported in this way.
Most success in implementing the DCCT recommenda-
tions is reported from well-resourced units using diabetes
clinical nurse consultants.
While it is recommended that adolescents with type 1
diabetes receive intensive therapy, schedules need to be
individualised. For example, some schoolchildren need
insulin at afternoon tea, most adolescents need longer-
acting insulin before bed for night control, and many
preschoolers are managed on intermediate-acting insulin in
the morning with small doses of insulin analogues to cover
hyperglycaemia later in the day. Insulin pumps may provide
the best solution for some patients, especially those with
frequent hypoglycaemia or hypoglycaemic unawareness, but
without government subsidy they are not affordable for most
families. None of these options are easy for children and
their families and, for some, intensive therapy is not possi-
ble. Insulin omission and chronic poor glycaemic control
remain problems in adolescence and require ongoing inter-
vention.10
The NSW and ACT study has demonstrated a relatively
fast decline in HbA1c levels
3 since the DCCT findings.
However, glycaemic control (and risk of long term vascular
complications) is unlikely to improve further in population
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studies unless multidisciplinary resources increase. It is
especially relevant for more educators to be trained in the
unique problems of improving control in this age group, and
for their expertise to be available to all children.
Jennifer J Couper
Head, Diabetes and Endocrinology
Women’s and Children’s Hospital, North Adelaide, SA, and
Associate Professor, University of Adelaide
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Potential pitfalls of healthcare performance indicators
The validity of use of indicators for judging performance depends on the rigour of the available data
PUBLICLY AVAILABLE REPORTS of “surgical waiting
times” are, at face value, of interest to patients and referring
doctors wishing to access surgical care. Such information
might be expected to provide a reasonable indication of the
absolute time to surgical intervention for an individual
patient, and allow reasonable conclusions to be drawn on
the relative performance (in terms of waiting times) of
surgical services.
Surgical waiting times are a specific example of “health-
care performance indicators” (see Definition). In addition to
providing information for users, such indicators are likely to
inform the opinions of politicians, journalists, hospital man-
agers and state and federal health departments on the
adequacy of our healthcare system and relative hospital or
regional performances. They may be used to construct
“league tables” of the relative performance of surgical units
— individual hospitals, surgical units or surgeons may be
deemed to have “good” or even “substandard” performance.
Public outcries and political pointscoring are likely to ensue.
Good indicators should be easy to understand and use by
the intended audience. Depending on how these data are
collected, processed and presented, reported waiting time
data might or might not provide useful information to
people seeking guidance on time to treatment. Reports of
surgical waiting times that use different definitions of “wait-
ing time”, or simply report on past performance, are of
limited value. Waiting time data presented as the frequency
with which a certain proportion of patients receive treat-
ment within a stated time (eg, 75% treated within 4 weeks)
may also fail to adequately inform patients or general
practitioners as to likely delays. Few existing systems are
capable of adjusting for delays before initial surgical consul-
tation (ie, waiting time to get onto the surgical waiting list),
let alone factors such as primary illness severity, comorbid-
ity or health insurance status — all of which influence actual
waiting times.
In this issue of the Journal (page 253), Cromwell et al
report an assessment of the utility of information regarding
surgical waiting times available on the World Wide Web.1
Their findings indicate that current Web-derived informa-
tion has significant shortcomings in data quality. They
conclude that waiting time data currently published on the
Web are, by and large, unsuitable for informing either
clinician referral or patient decision-making.1
This critique should not be misinterpreted as an example
of the well-recognised “dot.com” data reliability phenome-
non. It is not just Web-based sources of such data that are
open to criticism. Analysis of healthcare performance indi-
cator data derived from any existing sources would generate
similar critiques, with similar caveats required on interpre-
tation and use.2,3 The appropriate desire to develop per-
formance indicators in healthcare has often seen a race to
deliver indicators overwhelm the need for methodological
rigour in development and implementation. All too often,
too little emphasis is placed on initial identification of who
will use the indicator and how and why they will apply the
data. The absence of such ab initio clarity of purpose leads
to performance indicators that do not meet the needs and
expectations of consumers, providers or purchasers of
healthcare services.2-5
Definition
Healthcare performance indicators: statistics or other units of 
information which reflect, directly or indirectly, the performance of 
the healthcare system in maintaining or increasing the well-being of 
its target population.
